Some patients with advanced pancreatic cancer who harbor BRCA1 or BRCA2 mutations derived clinical benefit from rucaparib, according to study results.
Rucaparib (Rubraca, Clovis Oncology) — a PARP inhibitor approved by FDA for maintenance treatment of certain women with ovarian, fallopian tube or primary peritoneal cancers — also exhibited a tolerable safety profile. Read more . . .